Latest news
Debiopharm’s IAP Antagonist Significantly Improves Overall Survival of High-Risk Head & Neck Cancer Patients
Nucleai Secured $6.5m Series-A Initial Closing Led by Debiopharm to Advance Ai-Powered Precision Oncology Platform
Debiopharm’s novel microbiome remodeling program licensed to Takeda for the treatment of gastrointestinal disorders
Debiopharm partners with Verity Pharmaceuticals for the exclusive US commercialization of Trelstar® for Prostate Cancer
Acquisition of Debiopharm’s Investment Portfolio Company Kaiku Health Broadens Patient Access to Digital Oncology Intervention
Le Challenge pour la Qualité de vie du patient 2020 est maintenu et le délai de remise des projets prolongé…
Debiopharm expands its radiopharmaceutical footprint with an exclusive in-licensing agreement of 3B Pharmaceutical’s targeted CAIX radiotherapy
Debiopharm Advances into the Highly Anticipated Clinical Phase for their Potent WEE1 Inhibitor
FDA grants Breakthrough Therapy Designation for Debiopharm’s novel chemo-radio sensitizer Debio 1143 for front-line treatment of Head & Neck Cancer
Stay informed
Don't miss any latest news and announcements on Debiopharm Investment, subscribe to our newsletter.